All News
Cardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Read Article
SPAR Predicts ILD Progression in Systemic Sclerosis
The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding.
Read Article
The RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Read Article
The Hazardous Highs and Lows of Uric Acid
Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.
Read Article
Mortality Predictors in Rheumatoid Arthritis
A population based study from southern Denmark finds excess mortality RF-positive males with rheumatoid arthritis (RA) and that employment status and comorbidity were independent predictors of mortality.
Read Article
Mortality Risks Shift in Granulomatosis with Polyangiitis
Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.
Read Article
The RheumNow Week in Review – Why Comorbidity is Like the Weather (5.3.18)
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
Read Article
FDA Advisors Weigh COX-2 Inhibitor Safety
Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?
Read Article
FDA Review: Take Two for Baricitinib
FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.
Read Article
Tobacco Associated Deaths in the USA
JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall mortality risk, and a much highers cancer mortality risk compared to nonsmokers.
Read Article
Increased Comorbidity Burden in Lupus African Americans
Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, an
Read Article
Rituximab May Halt ILD in Antisynthetase Syndrome Myositis
A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most.
Read Article
The RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read Article
FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk
Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes.
Read Article
Anakinra May Attenuate Stroke Outcomes
The journal Stroke has published a trial wherein the use of subcutaneous IL-1Ra (anakinra) was shown to reduce the peripheral inflammatory response in those with an acute ischemic stroke.
Read Article
CARES Study- More CV Deaths with Febuxostat
The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat.
Read Article
2017 Rheumatology Year in Review
This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017. In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.
Read Article
Probenecid Benefits Heart Failure
In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation.
Read Article
Equal Cardiovascular Risks in Hypertensive Patients Treated with Selective and Nonselective NSAIDS
A Taiwanese study of 55,629 hypertensive patients shows no increased risk of major cardiovascular events comparing outcomes of patients started on COX-2 selective NSAIDs compared with nonselective NSAIDs (including ibuprofen, diclofenac and naproxen).
Read Article
Calcium and Vitamin D Do Not Increase Cardiac Events/Death
An analysis of the UK Biobank study found no link between calcium/vitamin D supplementation and incident cardiovascular events/deaths in a large prospective study of 475,255 men and women aged 40 to 69 years.
Read Article
